Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06658002 · ClinicalTrials.gov registry record · Phase 3
Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
A Phase 3 study of Corneal Ulcer and Fungal Keratitis, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT06658002: Recruiting Phase 3 study of Corneal Ulcer and Fungal Keratitis, sponsored by University of California, San Francisco.
NCT06658002 is a Phase 3 study of Corneal Ulcer and Fungal Keratitis that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06658002, a Phase 3 study of Corneal Ulcer and Fungal Keratitis, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.
Conditions Studied
Interventions
- DRUG Cyclosporine A
- OTHER Placebo Comparator: Placebo
Study Locations (2)
California
- University of California, San Farncisco - San Francisco
Tamil Nadu
- Aravind Eye Institute - Pondicherry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 3 |
What NCT06658002 shows while recruiting
NCT06658002 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Corneal Ulcer appearing as the primary indexed condition, and to 2 interventions - of which Cyclosporine A is the first listed.
NCT06658002 reports a single indexed study location in California, Tamil Nadu.
Frequently Asked Questions
What is clinical trial NCT06658002 about?
NCT06658002 is a clinical study titled "Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A". The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.
What is the current status of trial NCT06658002?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2025-09-01. Estimated completion is 2027-09-01.
What conditions does trial NCT06658002 study?
This clinical trial studies the following conditions: Corneal Ulcer, Fungal Keratitis.
What interventions are being tested in trial NCT06658002?
The interventions under investigation include: Cyclosporine A (DRUG), Placebo Comparator: Placebo (OTHER).
Who is sponsoring clinical trial NCT06658002?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06658002 being conducted?
This trial has 2 study locations across California, Tamil Nadu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Corneal Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06658002's enrollment target sits among peer trials
150 1520th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI